Whitehawk Therapeutics (NASDAQ:WHWK) Stock Falls 4.6% – Time to Sell?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares were down 4.6% on Thursday. The stock traded as low as $3.25 and last traded at $3.30. 523,161 shares were traded during trading, an increase of 54% from the average session volume of 339,868 shares. The stock had previously closed at $3.46.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on WHWK. Stifel Nicolaus initiated coverage on shares of Whitehawk Therapeutics in a report on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price target on the stock. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Leerink Partners began coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Whitehawk Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

Whitehawk Therapeutics Stock Performance

The stock’s fifty day moving average is $3.86 and its 200 day moving average is $3.83. The stock has a market cap of $184.71 million, a P/E ratio of -2.89 and a beta of 0.92.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. Equities research analysts predict that Whitehawk Therapeutics, Inc. will post -1.00 EPS for the current year.

Institutional Trading of Whitehawk Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp purchased a new position in Whitehawk Therapeutics during the 1st quarter valued at $40,000. Two Sigma Securities LLC bought a new position in Whitehawk Therapeutics in the 2nd quarter valued at $46,000. Deutsche Bank AG purchased a new stake in Whitehawk Therapeutics in the second quarter worth $145,000. Bank of America Corp DE purchased a new stake in Whitehawk Therapeutics in the second quarter worth $159,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Whitehawk Therapeutics in the first quarter worth $187,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.